前 言

冬至阳生，岁回律转。当举国上下全面推行中国式现代化促进各项事业高质量发展的浪潮中，中医内科学教育部重点实验室全体成员携手奋进、共同努力，学术论文产出质量稳步提升。

2023年共计发表学术论文111篇，SCI收录46篇，影响因子合计301.62，中科院1区14篇，2区11篇，单篇最高影响因子39.00；中文期刊65篇，均为核心期刊。

2024年，回望来时路，我们满怀豪情，展望新征程，我们更添信心。全体同仁将传承精华、守正创新、发展新质生产力，鼓励学科交融，凝心聚力，促进中医药事业高质量发展！

英 文 文 章

1.   心血管病方向

[1] Chen J^#, Wei X^#, Zhang Q, Wu Y, Xia G, Xia H, Wang L, Shang H^*, Lin S^* The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms。Acta Pharmaceutica Sinica B，2023 May 13(5):1919-1955. (SCI收录，一区，IF 14.903) ...........................................................................1

[2] Wei X^#, Liu W^#, Jiang W, Lan T, Pan H, Ma M, You L, Shang H^*. XinLi formula, a traditional Chinese decoction, alleviates chronic heart failure via regulating the interaction of AGTR1 and AQP1. Phytomedicine. 2023 Feb 23;113:154722. doi: 10.1016/j.phymed.2023.154722. (SCI收录，一区，IF 7.9)......................................2

[3] Zhao D^#, Guo K^#, Zhang Q, Wu Y, Ma C, He W, Jin X, Zhang X, Wang Y*, Lin S*, Shang H* Mechanism of XiJiaQi in the treatment of chronic heart failure: Integrated analysis by pharmacoinformatics, molecular dynamics simulation, and SPR validation .Computers in Biology and Medicine 2023.Sep(SCI收录，一区IF 7.7)………….………………………………………………………………………....3

[4] Han S^#, Xu Q^#, Pan H, Liu W, Dai Q, Lin H, Cui H, You L, Wu Y, Wei X^*, Shang H^*. Network pharmacology and molecular docking prediction, combined with experimental validation to explore the potential mechanism of Qishen Yiqi pills against HF-related cognitive dysfunction. J Ethnopharmacol. 2023 Oct 5;314:116570. doi: 10.1016/j.jep.2023.116570. （SCI收录，一区，IF 5.4）.......................................4

[5] Teng Y, Li Y, Wang L, Wang B, Su S, Chen J, Lu Z, Zhu H^*, Zhao M^*. Effectiveness and pharmacological mechanisms of Chinese herbal medicine for coronary heart disease complicated with heart failure. Journal of ethnopharmacology 2023, 322: 117605. （SCI收录，一区，IF 5.4）.........................................5

[6] Wang L, Lu Z, Teng Y, Pan W, Li Y, Su S, Chang J*, Zhao M*. Cognitive impairment is associated with BDNF-TrkB signaling mediating synaptic damage and reduction of amino acid neurotransmitters in heart failure. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2024, 38(1): e23351.（SCI收录， IF 4.8）……………………...6

[7] Su S, Ji X, Li T, Teng Y, Wang B, Han X, Zhao M*. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front Cardiovasc Med 2023, 10: 1291450.（SCI收录， IF 3.6）..................................................................7

2.脑血管病方向

[8] Zhuo Y, Chang J, Chen Y, Wen C, Chen F, Li W, Gao M, Luo W, Wan S, Song L*, Zhu L*. Value of contrast-enhanced MR angiography for the follow-up of treated brain arteriovenous malformations: systematic review and meta-analysis. Eur Radiol. 2023 ;33(10):7139-7148.（SCI收录， IF 5.9）…………………………………….8

[9] Li Y^#, Tao C^#, An N, Liu H, Liu Z, Zhang H, Sun Y, Xing Y*, Gao Y*. Revisiting the role of the complement system in intracerebral hemorrhage and therapeutic prospects. Int Immunopharmacol. 2023 Aug 7（SCI收录，二区，IF 5.6）...............................................................................................................................9

[10] Li W, Li X, Li Y, Chen Y, Zhu L*, Guo R*.Diagnostic value of MicroRNAs for depression: A systematic review and meta-analysis. J Psychiatr Res. 2023;157:132-140. （SCI收录,二区， IF 4.8）......................................................................................10

[11] Li W, Li X, Li Y, Chen Y, Zhu L, Guo R*. Association between mitochondrial DNA levels and depression: a systematic review and meta-analysis. BMC Psychiatry. 2023;23(1):8664.4.（SCI收录, IF 4.4）....................................................................11

[12] Gao M, Zhu L, Chang J, Cao T, Song L, Wen C, Chen Y, Zhuo Y, Wang F *.Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clin Drug Investig. 2023;43(1):1-11.（SCI收录，IF 3.2）........................................................................................................12

3. 肾脏病、内分泌、风湿免疫方向

[13] Zheng Q^#,Wang Y^#,Yang H, Sun L, Zhang P, Zhang X, Guo J,Liu Y*,Liu W*.Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis.2023 Apr（SCI收录，一区, IF 13.2）..........................................................................................................................13

[14] Huang W,Hong S,Zhu X,Mina H Alsaeedi,Hui Tang,James D Krier,Deep Gandhi,Kyra L Jordan,Ishran M Saadiq,Yamei Jiang,Alfonso Eirin,Lilach O Lerman.Obesity Blunts the Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles. Kidney Int Rep.2023 Jul（SCI收录，二区,IF 6.0）..................................14

[15] Ai S^# , Li Y^# , Zheng H, Wang Z, Liu W, Tao J, Li Y, Wang Y*.Global research trends and hot spots on autophagy and kidney diseases: a bibliometric analysis from 2000 to 2022 Frontiers in Pharmacology.2023.Nov  （SCI收录，二区，IF 5.6）............................................................................................................................15

[16] Zhang M^#, Cheng J^# , Luo J, Li C, Hou T, Zhao Y, Wang Y*, Qu H* , Kong H*.Protective effects of Scutellariae Radix Carbonisata-derived carbon dots on blood-heat and hemorrhage rats.Frontiers in Pharmacology.2023.Aug.10. （SCI收录，二区, IF 5.6)..............................................................16

[17] Li D, Liu W, Sun S, Zhang Y, Zhang P, Feng G, Wei J, Chai L*. Chinese herbal formula, modified Xianfang Huoming Yin, alleviates the inflammatory proliferation of rat synoviocytes induced by IL-1β through regulating the migration and differentiation of T lymphocytes. Journal of Ethnopharmacology. 2023 Jun 10; （SCI收录，一区，IF 5.4)..........................................................................................................................17

[18] Chen H, Guo J, Cai Y, Zhang C, Wei F, Sun H, Cheng C, Liu W*, He Z*. Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification. Journal of Ethnopharmacology. 2023 Nov 23（SCI收录，一区，IF 5.4)..............................................................................................................................18

[19] Wang Y, Liu T, Cai Y, Liu W*, Guo J*. SIRT6's function in controlling the metabolism of lipids and glucose in diabetic nephropathy Front Endocrinol (Lausanne).2023 Oct （SCI收录，二区，IF 5.2）...............................................19

[20] MengL^#, Li J ^#, Wang Y, Yuan M,Gui Z, Zhen C, Cun S, Wang M,Xiang Z , Yang C, Wang Yu, Zhang W *, Nan W*,Wang Y*. Association between serum complements and kidney function in patients with diabetic kidney disease Trials.Front Med (Lausanne).2023 Feb 25;9:793203. （SCI收录， IF 5.2）...............................20

[21] Feng G, Zhang P, Huang J, Yu Y, Yang F, Zhao X, Wang W, Li D, Sun S, Niu X, Chai L*, Li J*. Sequential Release of Panax Notoginseng Saponins and Osteopractic Total Flavone from Poly (L-Lactic Acid) Scaffold for Treating Glucocorticoid-Associated Osteonecrosis of Femoral Head. Journal of Functional Biomaterials 2023 Jan 4;（SCI收录, 二区，IF 4.8）......................................................................21

[22] Li Y, Lu H, Guo J, Zhang M, Zheng H, Liu Y,Liu W*. Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysisRes. Annals of Medicine 55:1, 2215542, DOI:10.1080/07853890.2023.2215542 （SCI收录, IF 4.4）..................................22

[23] Qiu Y, Tang J, Zhao Q, Jiang Y, Liu Y *, Liu W *.From Diabetic Nephropathy to End-Stage Renal Disease: The Effect of Chemokines on the Immune System. J Diabetes Res.2023 May（SCI收录， IF 4.3）...................................................................23

[24] Han Y, Zheng H, Du B, Zhang Y, Zhu X, Li J, Wang Y *, Liu W*. Role of Gut microbiota, Immune imbalance, and Allostatic load in the Occurrence and Development of Diabetic Kidney DiseaseJournal of diabetes research..2023 Dec 5 （SCI收录， IF 4.3）........................................................................................................24

[25] Lu H, Xie D, Qu B, Li M, He Y*, Liu W*. Emodin prevents renal ischemia-reperfusion injury via suppression of p53-mediated cell apoptosis based on network pharmacology. Heliyon. 9 (2023) e15682（SCI收录， IF 4.0）............................................................................................25

[26] Ai S, Li Y, Tao J, Zheng H, Tian L, Wang Y*, Wang Z*, Liu W *,Bibliometric visualization analysis of gut-kidney axis from 2003 to 2022. Frontiers in Physiology. 2023Jun DOI 10.3389/fphys.2023.1176894（SCI收录， IF 4.0）.................................................................26

[27] Yu B, Zhou M, Dong Z, Zheng H, Zhao Y, Zhou J , Zhang C, Wei F, Yu G, Liu W, Liu H, Wang Y*.Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy. PHARMACEUTICAL

BIOLOGY 2023, VOL. 61, NO. 1, 1222–1233（SCI收录， IF 3.8）...................27

4. 循证评价方向

[28]  Liu S, Yao C, Xie J, Liu H, Wang H, Lin Z, Qin B, Wang D, Lu W, Ma X, Liu Y, Liu L, Zhang C, Xu L, Zheng R, Zhou F, Liu Z, Zhang G, Zhou L, Liu J, Fei A, Zhang G, Zhu Y, Qian K, Wang R, Liang Y, Duan M, Wu D, Sun R, Wang Y, Zhang X, Cao Q, Yang M, Jin M, Song Y, Huang L, Zhou F, Chen D, Liang Q, Qian C, Tang Z, Zhang Z, Feng Q, Peng Z, Sun R, Song Z, Sun Y, Chai Y, Zhou L, Cheng C, Li L, Yan X, Zhang J, Huang Y, Guo F, Li C, Yang Y, Shang H^*, Qiu H; EXIT-SEP Investigators. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. 2023 Jul 1;183(7):647-655.. (SCI收录，一区，IF 39)........................................................................................28

[29] Liyuan Tao, Jiaojiao Liao, Xiaoyu Zhang , Rui Zheng , Shang H^*Association of medicinal plant consumption with all-cause mortality and cognitive impairment in older adult: A large prospective cohort study Phytomedicine 119 (2023) 154995  (SCI收录，一区， IF 7.9) ................29

[30] Liu L, Wang Y, Zhang P, Qiao H, Sun T, Zhang H, Xu X^*, Shang H^*. Collaborative Transfer Network for Multi-Classification of Breast Cancer Histopathological Images. IEEE J Biomed Health Inform. 2023 Jun 9;PP. doi: 10.1109/JBHI.2023.3283042. Epub ahead of print. PMID: 37294651. (SCI收录，一区，IF 7.7)...................................30

[31] Liu L, Chang J, Liu Z, Zhang P, Xu X^*, Shang H^*. Hybrid Contextual Semantic Network for Accurate Segmentation and Detection of Small-Size Stroke Lesions From MRI. IEEE J Biomed Health Inform. 2023 Aug;27(8):4062-4073. doi: 10.1109/JBHI.2023.3273771. Epub 2023 Aug 7. （SCI收录，一区，IF 7.7）.....31

[32] Zheng R, Chen Z, Guan Z, Zhao C, Cui H, Shang H^*. Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection. Chin Med. 2023 Feb 13;18(1):15. doi: 10.1186/s13020-023-00718-8. PMID: 36782216; PMCID: PMC9923652.（SCI收录，IF 4.9）.......32

[33] You L, Dai Q, Zhong X, Yu D, Cui H, Kong Y, Zhao M, Zhang X, Xu Q, Guan Z, Wei X, Zhang X, Han S, Liu W, Chen Z, Zhang X, Zhao C, Jin Y, Shang H*. Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population. J Integr Med. 2023 Sep;21(5):441-454. doi: 10.1016/j.joim.2023.08.001. Epub 2023 Aug 5. PMID: 37596131.（SCI收录，IF 4.8）........................................................................................................................... 33

[34] Xie Y, Han F, Jin Y, Ding Y, Guo J, Ji D, Zhang T, Chen X, Shang H^*. Organic Integration of Traditional Chinese and Western Medicines-Future of Clinical Practice Guidelines of Integrated Traditional Chinese and Western Medicines. Chin J Integr Med. 2023 Aug 2. doi: 10.1007/s11655-023-3739-9. Epub ahead of print. PMID: 37528326.（SCI收录，IF 2.9）...............................................................................................34

5. 中药药理及作用机制方向

[35] Liu Y ^#, Xia G ^#, Chen Y, Xia H, Xu J, Guo L *, Lin S*, Liu Y*. Purpurolide C-based microneedle promotes macrophage-mediated diabetic wound healing via inhibiting TLR4-MD2 dimerization and MYD88 phosphorylation. Acta Pharmaceutica Sinica B,2023 Dec.12 (SCI收录，一区，IF 14.903).......................................................................35

[36] Wang L ^#, Xia G ^#, Xia H, Wei X, Wang Y, Lin S*. (+)/(-)-Yanhusamides A-C, three pairs of unprecedented benzylisoquinoline-pyrrole hetero-dimeric alkaloid enantiomers from Corydalis yanhusuo. Acta Pharmaceutica Sinica B,2023 Feb (SCI收录，一区，IF 14.903)................................................................................................36

[37] Xia G, Xiao B, Wang L, Xia H , Wu Y , Wang Y, Shang H , Lin S^?. (+)/(?)-Yanhusuosines A and B, two dimeric benzylisoquinoline-protoberberine alkaloid atropo-enantiomers featuring polycyclic skeletons from Corydalis yanhusuo. Chinese Chemical Letters.2023 Jur（SCI收录，IF 9.1）.......................................................37

[38] Li S, Du H, Gan Dn, Li X, Zao X*, Ye Ya*. Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in hepatocellular carcinoma. Frontiers in Pharmacology. 2023, 14. (SCI收录, 二区, IF 5.6)....................................................38

[39] Cao X, Zhang N, Chen H, Wang W, Liang Y, Zhang J, Liu R, Li S, Yao Y, Jin Q, Guo Z, Chen Y, Gong Y, Li X, Zao X*, Ye Y*. Exploring the mechanism of JiGuCao capsule formula on treating hepatitis B virus infection via network pharmacology analysis and in vivo/vitro experiment verification. Front Pharmacol 2023, 14: 1159094..( SCI收录，二区, IF 5.6)..........................................................................39

[40] Zhang J^#, Zao X^#, Zhang J^#, Guo Z, Jin Q, Chen G, Gan D, Du H, Ye Y*. Is it possible to intervene early cirrhosis by targeting toll-like receptors to rebalance the intestinal microbiome? Int Immunopharmacol 2023, 115: 109627.( SCI收录，二区，IF 5.6)……………………………………………………………………………......40

[41] Wang L,Xia G, Xia H, Wei X, Lin S* (±)-Yanhusuomide A, a pair of ornithine-fused benzylisoquinoline enantiomers from Corydalis yanhusuo Bioorganic Chemistry.2023 Apr 15;（SCI收录，一区, IF 5.307）...........................................41

[42] Li S^#, Li Z^#, Du H, Zao X, Gan D, Yang X, Li X*, Xing Y*, Ye Y* Identification of pseudo-immune tolerance for chronic hepatitis B patients: Development and validation of a non-invasive prediction model. Front Public Health 2023, 11: 1137738.

（SCI收录，二区，IF 5.2）................................................................................... 42

[43] Feng G, Liu W, Yu Y, Tian B, Zhang Y, Yang F, Huang J, Zhang P, Wang W, Li D, Sun S, Niu X*, Chai L*, Li J* Angiogenesis coupled with osteogenesis in a bone tissue engineering scaffold enhances bone repair in osteoporotic bone defects. Biomedical Materials.2023 May  18 (2023) 045002（SCI收录，IF 4.0）................................43

[44] Wang W., Cao X, Cao Y, Liu L, Zhang S, Qi W, Zhang J, Yang X, Li X, Zao X *, Ye,Y *. Exploring the Molecular Mechanism of Niuxi-Mugua Formula in Treating Coronavirus Disease 2019 via Network Pharmacology, Computational Biology, and Surface Plasmon Resonance Verification. Curr Comput Aided Drug Des. Published online October 18, 2023.（SCI收录，IF 1.7）.........................................................44

[45] Wang M, Liu L, Wang Y, Liang Y, Li G, Lu X, Liu M, Yang H, Liu Z, Lin Z, Wang Z, Zao X*, Zhang S*. A new rat model of chronic relapsing ulcerative colitis with traditional Chinese medicine syndrome of yang deficiency and dampness stagnation. Pharmacological Research - Modern Chinese Medicine 2023, 8: 100295....................45

[46] Zao X, Cao X, Liang Y, Zhang J, Chen H, Zhang N, Liu R, Jin Q, Chen Y, Li X, Du H, Chen G, Hou L, Ye Ya*. The Chinese herbal KangXianYiAi formula inhibits hepatocellular carcinoma by reducing glutathione and inducing ferroptosis. Pharmacological Research - Modern Chinese Medicine 2023, 8: 100276...................46

备注：#：共同第一作者；*：通讯作者

中 文 文 章

1. 心血管病方向

[1] 苏莎,王蕾,陆梓雯,郭自强,赵明镜^*.从“心脾相关”理论探讨心力衰竭心脏能量代谢障碍 [J]. 中西医结合心脑血管病杂志, 2023, 21 (03): 562-566.............................................................................................................................47

[2] 程炜婷, 张婷, 金秋硕, 马喆, 吴爱明, 薛程元, 高永红, 聂波, 赵明镜, 娄利霞^*. 黄芪注射液对血管紧张素Ⅱ诱导的H9c2细胞凋亡的抑制作用和机制研究 [J]. 中西医结合心脑血管病杂志, 2023, 21 (01): 40-45........................................................................................................48

[4] 吕梦, 纪晓迪, 刘珂珂, 娄利霞, 聂波, 赵久丽, 吴爱明^*. 稳心颗粒调节心肌梗死大鼠心肌缝隙连接蛋白43表达及自噬的研究 [J]. 中西医结合心脑血管病杂志, 2023, 21 (03): 426-431. ..................................................................................................................50

[5] 纪晓迪,杨丁,崔喜元,娄利霞,聂波,赵久丽,赵明镜,吴爱明^*.芪苈强心胶囊对心肌梗死大鼠心脏IP3Rs/GRP75/VDAC1基因调控的机制研究[J].海南医学院学报,2023,29(11):815-82................................................................................... 51

[6] 许倩倩,韩松洁,尤良震,卫晓红^*,商洪才.中药干预肿瘤患者化疗后并发心律失常的系统评价和网状Meta分析[J].中草药,2023,54(24):8180-8190....52

[7] 潘海娥,刘文静,韩松洁,尤良震,张心怡,代倩倩,许倩倩,林宏远,孔一帆, 卫晓红^*,商洪才^*芪参益气滴丸改善大鼠心肌梗死气虚血瘀证的量效关系及作用机制[J].中华中医药杂志,2023,38(10):4688-4693. ....................................... 53

[8] 孔一帆^#,卫晓红^#,张迪,陈卓,许倩倩,樊晓丹,商洪才^*.基于CiteSpace对中医药治疗蒽环类所致心脏毒性的可视化分析[J].中草药,2023,54(19):6400-6412. ..............................................................................................................................54

[9] 楚心雨^#,卫晓红^#,吴雪芬,陈洁,夏欢,夏桂阳,林生^*, 商洪才^*.五法经典方辨治慢性心力衰竭的药理作用研究进展[J].中国中药杂志,2023,48(23):6324-6333.......................................................................................................................55

[10] 王志淼,朱海燕^*,赵勇,梁晋普,孟伟,高瑜倩,张冬梅.郭维琴教授从“毒、瘀、虚”论治经皮冠状动脉介入治疗术后胸痛[J].现代中医临床,2023,30(04):38-41. ........................................................................................................................56

[11] 杨睿,程序,赵梦竹,国倩倩,张馨月,刘梦华,魏琼,张冬梅^*.活血益气方对miR-484过表达脐静脉内皮细胞增殖、迁移和成管能力的影响[J].海南医学院学报,2023,29(09):660-665+673. .............................................................................57

[12] 王志淼,朱海燕^*,赵勇,梁晋普,孟伟,高瑜倩,张冬梅.郭维琴从“毒、瘀、虚”论治PCI术后胸痛[J].现代中医临床,2023,1-5. ..................................58

2. 脑血管病方向

[13] 陈燚,常静玲,李艳蓉,高梦霞,卓于迪,朱陵群^*.基于气血与脏腑理论分期论治缺血性脑血管病[J].环球中医药,2023,16(12):2502-2504. ..............................59

[14] 李文慧,朱陵群^*,王一帆,卓于迪,郭蓉娟.针刺治疗广泛性焦虑障碍的选穴及配伍规律研究[J].针灸临床杂志,2023,39(09):54-61. .......................................60

[15] 李文慧,朱陵群^*,郭蓉娟.探讨新冠病毒感染疫情下应激性失眠的中医治疗思路[J].辽宁中医杂志,2023,50(05):20-23. .........................................................61

[16] 卓于迪,朱陵群^*,张立山,戴雁彦,杨晓明,程潞瑶,苑艺,甘叶娜,周询,邬倩颖,郭烨,李多多.套索回归模型在中医临床研究数据的统计应用与R语言实践[J].世界中医药,2023,18(07):1033-1038. ...........................................................................62

3. 循证评价方向

[17] 张凯歌,商洪才^*,朱勇,黄为钧,张霄潇.建设中国中医药临床案例成果库，推动中医医案创新发展[J].中国实验方剂学杂志,1-5. ..............................63

[18] 翟静波,商洪才^*.基于贝叶斯单病例试验的中医个体化疗效动态评价方法[J].中国循证医学杂志,2023,23(11):1334-1339 ..........................................64

[19] 赖鸿皓,郭继华,尤良震,王伽伯,刘存志,刘玥,刘宝利,孙鑫,李慧,杨忠奇,季光,赵林华,赵晖,商洪才,曾芳,魏戌,张霄潇,葛龙.中医药临床研究类科技成果评价指标体系研究[J].中国全科医学,1-8..........................................65

[20] 饶映月,靳英辉,谢颖兰,商洪才,周仲瑜.中西医真正融合了吗？——一个基于中西医结合临床实践指南的系统评价[J].中国循证医学杂志,2023,23(10):1156-1164. ............................................................................................................66

[21] 郑蕊,胡明智,陈昭,孙杨,张晓雨,赵晨,陈卓,蒋寅,商洪才^*.数字孪生融入中西药联用个体化临床安全性评价思路[J].科学通报,2023,68(Z2):3758-3763....................................................................................................................................67

[22] 孙铭谣,田晨,李颖,石嘉恒,田金徽,刘昱,刘雅菲,刘雅洁,朱鸿飞,吴志雄,杨金亮,杨克虎,陈耀龙,周敏,周奇,柏涛,赵晨,商洪才,栗梦婷,董国菊,葛龙.药物治疗新型冠状病毒感染快速动态循证要览[J].中国循证医学杂志,2023,23(07):745-754. .............................................................................................68

[23] 张心怡,赵梦竹,林宏远,尤良震,关之玥,许倩倩,赵晨,商洪才^*.循证中医药发展助推新发突发传染病临床研究能力提升[J].中国循证医学杂志,2023,23(05):610-615. .......................................................................................................69

[24] 商洪才,张晓维.数智融合促进中医药传承创新发展[J].北京中医药,2023,42(05):464-466. ...............................................................................................70

[25] 邱瑞瑾,万思琦,关之玥,张心怡,商洪才^*.核心指标集在循证中医药学研究中的应用价值及前景分析[J].北京中医药,2023,42(05):470-474. ...........71

[26] 商洪才^*,李博.循证方法在中医领域的应用专题执行编委导读[J].北京中医药,2023,42(05):463. ....................................................................................72

[27] 田晨,孙铭谣,李颖,潘蓓,周奇,赵晨,刘昱,李玲,廖星,邓宏勇,吴大嵘,靳英辉,商洪才,田金徽,陈耀龙,杨克虎,刘杰,黄璐琦,葛龙.快速动态循证要览制订方法与流程[J].中国循证医学杂志,2023,23(04):450-456. .......................73

[28] 赖鸿皓,王浙,李滢,唐文静,王蓓蓓,孙培栋,孙铭谣,黄嘉杰,肖志攀,李颖,赵晨,商洪才,杨克虎,刘杰,葛龙.中医药多元证据整合方法学MERGE框架[J].协和医学杂志,1-12. .................................................................................................74

[29] 陈昭,郑蕊,邱瑞瑾,赵晨,王燕平,商洪才^*.基于数智融合的中西药并用代谢性药物肝损伤预警方法的构建[J].中华中医药杂志,2023,38(04):1413-1417....................................................................................................................................75

[30] 施秀青,李红艳,周婕,郭静,任相颖,靳英辉,商洪才^*.中医/中西医结合临床实践指南与专家共识中证据质量评价与推荐意见的应用现状分析[J].中医杂志,2023,64(06):581-586. ....................................................................................76

[31] 邱瑞瑾,魏旭煦,关之玥,胡明智,王春霞,史纪言,万思琦,张心怡,商洪才^*.中医药领域核心指标集研究现状及展望[J].中国循证医学杂志,2023,23(02):211-220. .....................................................................................................................77

[32] 王诗淳,李红艳,马文昊,阎思宇,黄桥,商洪才^*,靳英辉^*.基于中国临床试验注册中心的真实世界研究现况分析[J].中国循证医学杂志,2023,23(01):75-79....................................................................................................................................78

[33] 赖鸿皓,孙铭谣,黄嘉杰,李颖,宁金铃,赵威龙,唐文静,杨水华,田金徽,陈耀龙,商洪才,杨克虎,葛龙.中西医结合临床实践指南实施框架构建的思考[J].协和医学杂志,2023,14(01):31-38. ...................................................................79

[34] 徐愿,林生,刘铁钢,崔勇,李修洋,莫美,夏欢,白辰,张霄潇.中西医交叉创新促进中西医结合医学发展[J].北京中医药大学学报,2023,46(12):1653-1657..................................................................................................................................80

4. 中药药理及作用机制方向

[35] 李心怡,林生^*,林怡,苏友祥,王超,黄亮晴,赵静,田贵华.基于代谢组学探究豨芍方治疗神经性病理性疼痛的镇痛机制（英文）[J].Journal of Traditional Chinese Medical Sciences,2023,10(04):448-460+524............................81

[36] 张迪,陆瑞敏,盛春瑞,张冬梅,陈萌.小青龙汤及其方元对寒饮蕴肺证大鼠气道黏液高分泌及炎性因子的干预作用[J].中医药学报,2023,51(07):34-40...............................................................................................................................82

[37] 李心怡,林生^*,林怡,黄亮晴,谢晓明,田贵华.中药复方治疗疼痛的用药规律[J].中国中药杂志,2023,48(12):3386-3393. ............................................83

[38] 于博睿,周梦琪,周梦玲,郑慧娟,刘伟敬,王耀献^*.基于网络药理学和分子对接技术研究黄芩-黄连治疗糖尿病肾脏病机制[J].辽宁中医药大学学报,2023,25(07):45-54. .......................................................................................................84

[39] 朱荔炜,王春国,洑晓哲,黄为钧,李潇然,赵进喜^*.基于UHPLC-Q-Exactive Orbitrap MS和网络药理学探讨益气祛风方治疗糖尿病肾病作用机制[J].天津中医药,2023,40(11):1466-1477. .......................................................................85

5. 药物分析方向

[40] 杨漫芳,李慧,许心蕊,张晴玥,王添钰,冯露,夏桂阳,覃湛,聂波^*.基于UHPLC-LTQ-Orbitrap MS/MS探讨四妙勇安汤中木犀草素和山柰酚在大鼠体内的代谢产物及代谢规律[J].中国中药杂志,2023,48(22):6191-6199. ........................86

6. 中医理论方法

[41] 陈荟溪,郑慧娟,张佳乐,李垚锬,周少峰,艾思南,王耀献^*,刘伟敬,孙卫卫.从肾“个性”之“肾为水脏”谈肾脏疾病的治疗[J].时珍国医国药,2023,34(08):1949-1951..........................................................................................................87

[42] 陈洪宇,李侠,王珍,方敬爱,刘伟敬^*,刘玉宁^*.从伏邪论治慢性肾脏病的思路与方法[J].中国中西医结合肾病杂志,2023,24(07):656-658. ...............88

[43] 陈以平,王耀光,余仁欢,方敬爱,刘伟敬^*,刘玉宁^*.从三焦论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2023,24(01):92-94. ..................89

[44] 魏连波,彭建中,占永立,方敬爱,刘伟敬^*,刘玉宁^*.从卫气营血论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2023,24(05):468-470. .......90

[45] 周少峰,王耀献,郑慧娟,陈荟溪,孙卫卫,刘伟敬^*.“苦坚肾”治疗肾系疾病探骊[J].北京中医药大学学报,2023,46(04):572-576. ............................91

[46] 刘玉宁,谢院生,雷根平,郭立中,方敬爱,刘伟敬^*.从中医肾论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2023,24(03):280-282. .............92

7.肝肾脏病、内分泌、风湿免疫方向

[47] 贾英民,张轶斐,刘鹏,李长新,常静,戴浩然,刘伟敬,刘宝利.氧化应激指标、血管内皮损伤与慢性肾病患者磷脂酰丝氨酸外翻的关系[J].疑难病杂志,2023,22(12):1278-1284. ..........................................................................................93

[48] 李垚锬,侯金易,郑慧娟,周少峰,刘伟敬,王耀献^*.王耀献以病机为核心从“心-脾-肾轴”论治慢性肾脏病[J].中医学报,2023,38(12):2611-2616...94

[49] 李文歌,李平,王明,方敬爱,刘伟敬,刘玉宁^*.糖尿病肾病中西医诊治的思路与方法[J].中国中西医结合肾病杂志,2023,24(09):844-846..................95

[50] 李垚锬,吴霄畅,侯金易,郑慧娟,胡晓蒙,丁少唯,刘伟敬,王耀献^*.张聿青辨治吐血经验和特色[J].中医药导报,2023,29(11):200-202+205...........96

[51] 邱斌辉,李艳存,刘玉宁,刘伟敬^*.补肾健脾法治疗维持性血液透析便秘患者临床观察[J].山西中医,2023,39(08):41-42. ............................................97

[52] 于博睿,王耀献^*,柳红芳,刘伟敬,郑慧娟.“病-证+X”模式构建慢性肾脏病进展预测模型的思路与方法[J].中国中西医结合肾病杂志,2023,24(07):647-649. .............................................................................98

[53] 于博睿,周梦琪,周梦玲,郑慧娟,刘伟敬,王耀献^*.基于网络药理学和分子对接的黄芩-黄连治疗糖尿病肾脏病（DKD）的机制研究[J].辽宁中医药大学学报,1-18. ................................................................................................................99

[54] 周少峰,孙卫卫,吴巧茹,郑慧娟,李垚锬,刘伟敬,王耀献^*.从“伏风入络”探讨激素依赖型紫癜性肾炎的分期辨治[J].中医杂志,2023,64(04):417-421...................................................................................................................................100

[55] 孙霄,肖遥,孙一珂,胡孙林,祝广钦,黄为钧,王若冲,张海蓉,赵进喜^*,马淑然.基于“微型癥瘕”理论探讨糖尿病肾病的分期论治[J].中医药学报,2023,51(11):91-95. ......................................................................................................101

[56] 于博睿,周梦玲,郑慧娟,周梦琪, 刘伟敬,王耀献^*.基于网络药理学探讨牛蒡子治疗糖尿病肾病的作用机制[J].中国中西医结合肾病杂志,2023,24(01):54-56+100....................................................................................................................102

[57] 张耀夫,赵进喜^*,朱荔炜,倪博然,洑晓哲,王羲文,黄为钧.再谈糖尿病肾病“肾络伏风”病理机制及“从风论治”治法[J].中华中医药杂志,2023,38(08):3669-3673. .....................................................................................................103

[58] 张耀夫,赵进喜^*,朱荔炜,蒋里,周婧雅,黄为钧,肖永华,王世东,吕仁和.论消渴病火热病机[J].中华中医药杂志,2023,38(07):3198-3202. .............104

[59] 和莹,吕杰,康意,李元,柴立民,周静威.基于“阳化气，阴成形”理论治疗类风湿性关节炎[J].中医学报,2023,38(04):684-689. ...........................105

[60] 周少峰,李丹婷,蔡雨孜,陈荟溪,李傲霜,郑慧娟,孙卫卫,王耀献^*.王耀献从湿热理论谈肾脏病湿热证特点与治疗[J].中医学报,2023,38(09):1918-1924.................................................................................................................................106

[61] 刘怡秀,郑慧娟,王耀献^*.王耀献从藏象学说论治IgA肾病经验[J].山东中医杂志,2023,42(06):627-632. .....................................................................107

[62] 艾思南,郑慧娟,李丹婷,陶嘉茵,尹诗卉,曹博宁,康意,王耀献^*.基于数据挖掘探析王耀献教授治疗IgA肾病的用药规律[J].中国医药导报,2023,20(15):18-21+52. .........................................................108

[63] 郭小乐,于琦,郑慧娟,王耀献^*.基于数据挖掘的王耀献教授治疗慢性肾炎经验研究[J].世界中医药,2023,18(10):1469-1474. ..................................109

[64] 曹博宁,王珍,郑慧娟,郑酉友,王耀献^*.王耀献教授从“木郁达之”论治难治性尿路感染经验[J].辽宁中医杂志,1-7. ................................................110

[65] 郭小乐,艾思南,郑慧娟,王耀献^*.从六郁论治早期高血压肾损害[J].环球中医药,2023,16(01):138-140. ........................................................................111